Sabatolimab Not Yet Recruiting Phase 2 Trials for Myelodysplastic Syndrome Treatment

Back to Sabatolimab
IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04823624MBG453 in Lower Risk MDS